Timing clarification: Centene’s 2Q26 results are scheduled for release at approximately 6:00 a.m. ET on Tuesday, July 28, 2026, followed by an 8:30 a.m. ET earnings call. Since today is July 28, this is a pre-results preview based on information available before the release, rather than an event occurring “tomorrow.”
Centene enters 2Q with a much improved setup versus last year’s Marketplace-driven disruption. In 1Q26, the company reported $3.37 in adjusted EPS, roughly $0.50 above its own expectations, and increased its 2026 adjusted-EPS floor to more than $3.40 from more than $3.00. The key question now is how much of that first-quarter strength was truly durable—and, especially, whether the company can substantiate the expected Marketplace risk-adjustment benefit without re-creating the unpleasant surprise seen in 2Q25.
The most important message from this report will be whether Centene’s three-part recovery narrative remains intact:
A clean quarter should increase confidence that 2026 represents a genuine margin-recovery year. Conversely, any shortfall in Marketplace risk-adjustment assumptions, or evidence that Medicaid/Medicare medical trend is reaccelerating, would likely dominate the market reaction.
The most consequential item is the June Wakely data and Centene’s updated view of 2026 Marketplace risk adjustment.
In 1Q, Centene said its Silver-tier Marketplace membership had higher-than-expected medical costs because the post-enhanced-APTC market shift left it with a relatively higher-acuity population. Management argued that Marketplace risk adjustment should compensate it for that selection, and changed its year-end forecast to a slight risk-adjustment receivable, versus an earlier expected payable.
Crucially, the company incorporated only a partial benefit into its updated outlook:
This matters because 2Q25 was the period when Centene sharply reduced its Marketplace risk-adjustment revenue estimate, contributing to a $0.16 adjusted loss per share, a 93.0% consolidated HBR, and a major reset in investor confidence. The market is therefore unlikely to view a simple EPS beat as sufficient; investors will want evidence that the Marketplace receivable is supportable, conservatively booked, and not dependent on overly optimistic assumptions.
What investors should listen for:
Medicaid was a major source of 1Q upside. The segment’s HBR was 93.1%, improving 50 basis points year over year, supported by rate increases, lower-than-expected flu costs, favorable weather effects, and cost-management execution. Centene characterized the fundamental improvement as real, but did not assume that first-quarter outperformance would persist through the year.
The debate in 2Q is whether the improvement remains operationally driven after the transient 1Q benefits fade.
Management’s framework entering the year was:
| Medicaid variable | 2026 management framework |
|---|---|
| Composite rate yield | ~4.5% |
| Net medical-cost trend | Mid-4% range |
| Year-end Medicaid membership | Down ~6% from year-end 2025 |
| Margin objective | Continued improvement through 2026 and 2027 |
The operational levers are meaningful: utilization management, clinical programs, network optimization, payment integrity, fraud/waste/abuse efforts, and state-level benefit-design changes. Behavioral health, home health, and high-cost drugs remain core trend pressures, although Centene said it was seeing early stabilization in some behavioral-health and ABA-related utilization trends.
What would be constructive: a Medicaid HBR that is worse sequentially—as expected seasonally—but still evidences year-over-year improvement and supports the mid-4% net-trend outlook.
What would concern investors: a renewed trend spike, weaker state-rate alignment, adverse acuity shifts, or messaging that 1Q’s favorable result was predominantly flu/weather rather than repeatable execution.
Centene’s Medicare segment delivered an 84.9% HBR in 1Q, better than expected in both Medicare Advantage and PDP. This was an important contributor to the quarterly beat.
The challenge is that management was clear that Medicare HBR should rise throughout the year, particularly because PDP is a larger portion of the segment and has pronounced benefit-seasonality effects. Centene expects Medicare earnings to step down materially after 1Q, so a higher 2Q HBR in itself would not be surprising. The question is whether it rises in line with the planned slope.
PDP is a particular focus:
For Medicare Advantage, investors should watch the company’s confidence in its path to breakeven profitability in 2027, given elevated medical trend and the need for further pricing, quality, network, and care-management progress.
Centene cautioned in April that earnings should be heavily front-loaded:
This is important context. With $3.37 of adjusted EPS already reported in 1Q and full-year adjusted EPS guided to more than $3.40, the guidance floor implies only a modest aggregate contribution from the final three quarters. As a result, investors should focus less on whether 2Q EPS is optically strong and more on whether the company:
A guidance increase would be meaningful, but retaining the guidance while building confidence in the Marketplace receivable could also be viewed constructively.
| Metric | 1Q26 result / outlook | Why it matters in 2Q |
|---|---|---|
| Adjusted EPS | $3.37 in 1Q; FY26 >$3.40 | Tests whether 1Q upside is retained or reinvested in caution |
| Consolidated HBR | 87.3% in 1Q; FY26 90.9%–91.7% | Main measure of medical-cost execution and seasonal progression |
| Medicaid HBR | 93.1% in 1Q | Best read on margin-recovery durability |
| Commercial / Marketplace HBR | 75.3% in 1Q | Gross claims are less meaningful without risk-adjustment context |
| Medicare HBR | 84.9% in 1Q | Tests PDP and MA performance as seasonal costs rise |
| Marketplace pretax margin | ~3% embedded in guidance | Most important margin assumption to validate |
| Premium and service revenue | FY26 $171B–$175B | Watch for Medicaid rates/state-directed payments and mix |
| Adjusted SG&A ratio | 7.6% in 1Q; FY26 7.0%–7.6% | Cost discipline, product mix, and preparation for open enrollment |
| Debt / capitalization | 43.2% at 1Q end | Balance-sheet progress following $1B debt repayment |
| Days in claims payable | 48 days in 1Q | Reserve and claims-processing indicator; management expected a 1–2 day decline over the year |
A favorable report would likely include:
The upside case is not solely a 2Q beat. It is a report that makes the company’s 2026 Marketplace margin and 2027 earnings-power recovery feel more underwritten.
The principal downside risks are concentrated in a few areas:
Marketplace risk adjustment disappoints.
A lower-than-expected receivable—or a return toward a payable assumption—would revive concerns created by 2Q25 and call the full-year earnings outlook into question.
Medicaid trend reaccelerates.
Higher behavioral-health, home-health, specialty-drug, or acuity pressure could offset the benefit of rate increases and cost initiatives.
Medicare outperformance proves temporary.
A larger-than-planned rise in PDP or MA HBR would weaken the argument that 1Q was conservatively planned.
Guidance remains unchanged for the wrong reason.
Maintaining the EPS floor despite weaker underlying segment economics would likely be interpreted negatively, especially after the company’s very strong 1Q.
Policy uncertainty increases.
Centene remains exposed to changes in Medicaid funding and eligibility, work requirements, ACA subsidy policy, Marketplace program-integrity rules, and Medicare reimbursement. These are longer-duration risks, but they influence how investors value the recovery.
Centene’s 2Q26 report is primarily a confidence test in the Marketplace-risk-adjustment thesis and the durability of Medicaid margin recovery. The company has already established a favorable 1Q starting point: Medicaid execution improved, Medicare outperformed, balance-sheet leverage declined, and the Marketplace outlook shifted from a payable to a slight receivable.
But the market will remember that the 2Q25 report exposed a Marketplace-estimation problem. Therefore, the most valuable outcome is not simply better-than-expected EPS—it is specific, conservative, and credible evidence that the 2026 Marketplace receivable is real, alongside medical-cost ratios that remain consistent with the full-year framework.
Most important call question: How much of the expected Marketplace risk-adjustment benefit is now supported by June data, how much is reflected in guidance, and what residual upside or downside remains?